Apogee Therapeutics Inc. (NASDAQ:APGE - Get Free Report)'s stock price dropped 7.6% during trading on Tuesday . The stock traded as low as $36.70 and last traded at $36.26. Approximately 792,265 shares traded hands during trading, an increase of 35% from the average daily volume of 588,927 shares. The stock had previously closed at $39.24.
Analyst Ratings Changes
APGE has been the topic of several research analyst reports. Citigroup reissued a "buy" rating on shares of Apogee Therapeutics in a research note on Monday. Guggenheim reissued a "buy" rating and set a $116.00 price target on shares of Apogee Therapeutics in a research note on Wednesday, July 2nd. BTIG Research upped their target price on Apogee Therapeutics from $100.00 to $115.00 and gave the company a "buy" rating in a research note on Monday. Finally, Wedbush reaffirmed an "outperform" rating and issued a $90.00 target price on shares of Apogee Therapeutics in a research note on Monday. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Apogee Therapeutics presently has an average rating of "Buy" and an average target price of $99.00.
View Our Latest Report on Apogee Therapeutics
Apogee Therapeutics Trading Up 1.7%
The business has a 50 day moving average of $40.36 and a 200-day moving average of $38.93. The stock has a market cap of $1.70 billion, a PE ratio of -10.28 and a beta of 1.47.
Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.95) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.19) by $0.24. On average, equities research analysts anticipate that Apogee Therapeutics Inc. will post -3.09 EPS for the current fiscal year.
Insider Buying and Selling at Apogee Therapeutics
In other Apogee Therapeutics news, insider Carl Dambkowski sold 10,090 shares of the stock in a transaction on Wednesday, July 2nd. The stock was sold at an average price of $45.09, for a total transaction of $454,958.10. Following the transaction, the insider owned 238,998 shares of the company's stock, valued at $10,776,419.82. This represents a 4.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Over the last 90 days, insiders sold 15,540 shares of company stock worth $653,093. Corporate insiders own 42.77% of the company's stock.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the business. Brooklyn Investment Group purchased a new position in shares of Apogee Therapeutics during the 1st quarter worth $42,000. GF Fund Management CO. LTD. purchased a new position in shares of Apogee Therapeutics during the 4th quarter worth $43,000. AlphaQuest LLC acquired a new stake in shares of Apogee Therapeutics during the 1st quarter worth $43,000. GAMMA Investing LLC increased its holdings in shares of Apogee Therapeutics by 3,560.1% during the 1st quarter. GAMMA Investing LLC now owns 5,417 shares of the company's stock worth $202,000 after buying an additional 5,269 shares during the last quarter. Finally, Optimize Financial Inc acquired a new stake in shares of Apogee Therapeutics during the 4th quarter worth $203,000. Hedge funds and other institutional investors own 79.04% of the company's stock.
About Apogee Therapeutics
(
Get Free Report)
Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.
See Also
Before you consider Apogee Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apogee Therapeutics wasn't on the list.
While Apogee Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.